AMENDMENTS TO THE SPECIFICATION

Please replace the Abstract with the following:

The present invention provides a method for identifying a binding molecule having selective affinity for a ligand by selectively immobilizing a diverse population of binding molecules to a solid support, simultaneously contacting the diverse population immobilized on the solid support with two or more ligands and determining at least one binding molecule which selectively binds to one or more of the ligands.

AMENDMENTS TO THE CLAIMS

Please cancel Claims 2-5 and amend Claim 1 as follows:

Claim 1. (Amended) A method comprising:

a. providing:

i. a solid support coated with an anti-immunoglobulin reagent; and

ii. a phage expressed antibody library, wherein said library comprises about 10^4 or more of different binding molecule species; [and]

b. contacting said solid support [to] and said phage expressed antibody library to generate an antibody bound solid support;

c. contacting said antibody bound solid support with a sample containing antigen/s, wherein said contacting generates a solid support containing antibody-antigen complex/es;

d. identifying one or more antigens contained in said antibody-antigen complexes;

Claim 2. (Cancelled) The method of claim 1, wherein said contacting generates an antibody bound solid support.

Claim 3. (Cancelled) The method of claim 2, further comprising the step of c) contacting said antibody bound solid support with a sample containing antigens.

Claim 4. (Cancelled) The method of claim 3, wherein said contacting step of step c) generates a solid support containing antibody-antigen complexes.

Claim 5. (Cancelled) The method of claim 4, further comprising the step of d) identifying one or more antigens contained in said antibody-antigen complexes.

Claim 6. (original) The method of claim 4, further comprising the step of e) generating an immunoglobulin molecule that binds at least one antigen found in said antibody-antigen complexes.

Claim 7. (original) The method of claim 6, further comprising the step of f) treating a cell with said immunoglobulin.

Claim 8. (original) The method of claim 7, wherein said cell comprises a cancer cell.

Claim 9. (original) The method of claim 3, wherein said sample comprises a cell extract.

Claim 10. (original) The method of claim 9, wherein said cell extract comprises a cancer cell extract.

Claim 11. (original) The method of claim 10, wherein said cancer cell extract contains biotinylated proteins.

Claim 12. (original) The method of claim 11, wherein said biotinylated proteins comprise biotinylated membrane proteins.

Claim 13. (original) The method of claim 2, further comprising the step of contacting said antibody bound solid support with a label.

Claim 14. (original) The method of claim 1, wherein said phage expressed antibody library expresses antibody fragments.

Claim 15. (original) The method of claim 14, wherein said antibody fragments comprise antibody fragments reactive with surface expressed cancer polypeptides.

Claim 16. (original) The method of claim 1, wherein said solid support comprises a membrane.

Claim 17. (original) The method of claim 16, wherein said membrane comprises a nitrocellulose membrane.

Claim 18. (original) The method of claim 1, wherein said solid surface is further coated with a blocking agent.

Claim 19. (original) The method of claim 18, wherein said blocking agent comprises bovine serum albumin.

Claim 20. (original) The method of claim 1, wherein said anti-immunoglobulin reagent comprises anti-human antibody.

Claim 21. (original) The method of claim 20, wherein said anti-human antibody comprises anti-human kappa antibody.

Claim 22. (original) The method of claim 21, wherein said anti-human kappa antibody comprises goat anti-human kappa antibody.

Claim 23. (original) The method of claim 2, wherein said antibody bound solid support comprises more bound antibody than a control solid support lacking said anti-immunoglobulin reagent.